-
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatmentsKandolf Sekulović, Lidija ...Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these ... innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). MATERIALS AND METHODS: Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. RESULTS: The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p < 0.001), health expenditure per capita (r = 0.695; p < 0.001) and the Mackenbach score of health policy performance (r = 0.765; p < 0.001) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines. CONCLUSIONS: Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increaseVir: European Journal of Cancer. - ISSN 0959-8049 (Vol.75, 2017, str. 313-322)Vrsta gradiva - članek, sestavni delLeto - 2017Jezik - angleškiCOBISS.SI-ID - 2686587
Avtor
Kandolf Sekulović, Lidija |
Peris, Ketty |
Hauschild, Axel |
Stratigos, Alexander J. |
Grob, J. J. |
Nathan, Paul D. |
Dummer, R. |
Forsea, A.-M. |
Hoeller, C. |
Ocvirk, Janja
Teme
metastatski melanom |
zdravljenje |
razvojni indeks |
inovativna zdravila |
innovative medicines |
metastatic melanoma |
treatment |
human development index
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Kandolf Sekulović, Lidija | ![]() |
Peris, Ketty | ![]() |
Hauschild, Axel | ![]() |
Stratigos, Alexander J. | ![]() |
Grob, J. J. | ![]() |
Nathan, Paul D. | ![]() |
Dummer, R. | ![]() |
Forsea, A.-M. | ![]() |
Hoeller, C. | ![]() |
Ocvirk, Janja | 13541 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.